Guidelines for Prednisone Tapering from 40 mg

General Principles for Prednisone Tapering

The European League Against Rheumatism recommends tapering schedules should be individualized based on disease activity, laboratory markers, and monitoring for adverse events 1
Initial tapering should aim to reduce the dose to 10 mg/day within 4-8 weeks, as recommended by the European League Against Rheumatism 1, 2
Once at lower doses (below 10 mg), slower tapering at 1 mg every 4 weeks is recommended to minimize risk of adrenal insufficiency, according to the European League Against Rheumatism 1, 2
Single daily dosing is preferred over divided doses except in special situations, as suggested by the European League Against Rheumatism 1

Initial tapering: Reduce dose to 10 mg/day prednisone equivalent within 4-8 weeks, as recommended by the European League Against Rheumatism 1
Maintenance tapering: Once remission is achieved, taper daily oral prednisone by 1 mg every 4 weeks, according to the European League Against Rheumatism 1

For children with steroid-sensitive nephrotic syndrome: After achieving remission, transition to alternate-day dosing for at least 4 weeks, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 3, 4

Initial treatment should be reduced 15 days after disease control, as suggested by the British Association of Dermatologists 5
Gradual tapering with aim of stopping treatment 4-12 months after initiation, according to the British Association of Dermatologists 5

40 mg daily for 1-2 weeks, then taper by 5 mg every 1-2 weeks, as recommended by the European League Against Rheumatism 1, 6

For sudden hearing loss: After initial high-dose treatment, a representative tapering regimen uses maximum dose for 4 days, followed by a 10 mg taper every 2 days, as suggested by the American Academy of Otolaryngology-Head and Neck Surgery 7
Consider steroid-sparing agents in patients who develop significant steroid-related adverse effects or who require prolonged therapy, according to the European League Against Rheumatism and the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 1, 6

Tapering too quickly, especially at doses below 10 mg, which increases risk of adrenal insufficiency and disease relapse, as warned by the European League Against Rheumatism 1
Failing to monitor for signs of disease relapse during the tapering process, as emphasized by the European League Against Rheumatism 1
Underdosing when switching between different corticosteroids, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 7

For adults who have taken prednisone 40 mg daily for more than two weeks, taper the dose over 6–8 weeks, slowing the reduction once the dose falls below 15 mg to minimize the risk of adrenal insufficiency. 8
Initial phase (dose > 25 mg): decrease by 10 mg every 1–2 weeks; this faster pace is acceptable because adrenal insufficiency risk is lower at higher doses. 9 [10]
Intermediate phase (25 mg → 15 mg): decrease by 2.5–5 mg every 2–4 weeks; the 10–15 mg/day range is a critical threshold where disease relapses are more common, so extra caution is required. 9 [8]
Final phase (dose < 15 mg): decrease by 1.25–2.5 mg every 2–6 weeks; a very slow taper is needed because the risk of adrenal insufficiency becomes significant. 9 [10]

Perform each dose reduction only if the patient is asymptomatic and has a normal C‑reactive protein level, especially when the dose is below 25 mg/day. 9
Anticipate hypothalamic‑pituitary‑adrenal (HPA) axis suppression in any patient receiving more than 7.5 mg prednisolone‑equivalent daily for more than three weeks. 10

Give the entire daily dose as a single morning dose before 9 am; this regimen is as effective as divided doses and results in less HPA‑axis suppression. 8

Ulcerative colitis: taper from 40 mg over 6–8 weeks. 8
Recurrent pericarditis: employ an especially slow taper, reducing by 1.0–2.5 mg every 2–6 weeks once the dose reaches the 10–15 mg/day threshold. 9

Educate patients about the risk of adrenal insufficiency and how to prevent it during acute stress situations. 10
Provide appropriate glucocorticoid “stress‑dose” coverage for patients on chronic medium‑ or high‑dose therapy; this may involve increasing the oral dose for three days or switching to intravenous hydrocortisone, depending on clinical need. 10

All patients receiving glucocorticoids should be supplemented with calcium (≈1,200–1,500 mg/day) and vitamin D (≈800–1,000 IU/day). 9
Bisphosphonate therapy is recommended for men ≥ 50 years and post‑menopausal women who start long‑term glucocorticoid treatment at doses ≥5–7.5 mg/day prednisolone (or equivalent) to prevent bone loss. 9